Sign up Australia
Proactive Investors - Run By Investors For Investors
Why invest in CPT?
Concepta: THE INVESTMENT CASE

Concepta PLC raises £2mln in oversubscribed share placing and confirms key Chinese order has been placed

The proceeds from the fundraiser will be used to expand in the People's Republic and will invested in product development
couple looking at pregnancy test
INVESTMENT OVERVIEW: CPT The Big Picture
The company’s key product is myLotus, an easy-to-use home test that has been developed for women who have been trying to conceive for six months or more

Fertility specialist Concepta plc (LON:CPT) said it had conditionally raised £2mln in an over-subscribed share placing and announced the formal sign-off on a £600,000 Chinese deal.

The stock was sold at 7p – a modest discount to Friday’s close – and the proceeds will be used to fund its expansion in the People’s Republic, though some of the cash will be invested in new product development.

READ: Concepta expects 'transformational' 2018 as it tackles supply chain issues

WATCH; Concepta chief on Chinese deals 

Announced last Monday (Nov 6), the order for 5,200 myLotus fertility meters by the ShanDong WeiHai HaiChen Pharmaceutical Co has now been placed, with revenues from the deal expected to fall onto the top-line by the end of the year.

“We expect to be able to announce further orders in the coming months and I look forward to updating shareholders in due course," said chief executive Eric Henau.

In a separate announcement, its third of the morning, Concepta said it had appointed Novum Securities joint broker to work alongside Beaufort Securities.

Main product

The company’s key product is myLotus, an easy-to-use home test that has been developed for women who have been trying to conceive for six months or more.

It measures hormone levels in urine to give quantitative and qualitative measurements that might help explain the apparent lack of fertility.

Competitor products currently only allow qualitative measurement and are based on the 'average woman'.

On sale now in China, the commercial launch for myLotus in Germany and the UK is expected in the first half of next year, once the company has received regulatory sign-off in the form of a CE mark.

Stress tests the next development

Concepta has more than just myLotus in its armoury, though; it’s currently working on a stress test to help both women and men with fertility problems.

A technology transfer and licence agreement has been agreed with Selective Antibodies, a UK based diagnostics company.

Concepta will be given exclusive rights to rights to Selective’s intellectual property in return for fees and a royalty on any products sold.

At present, the Lotus platform capabilities include measurements of a woman's personal hCG and LH hormone levels.

With Selective’s input, Concepta wants to expand this reach to quantitative measurement of stress hormones such as cortisol. 

View full CPT profile View Profile

Concepta Timeline

Newswire
February 20 2018

Related Articles

Harley Street sign
December 07 2017
The injection will bankroll the continuing technical development of the firm’s first LIGHT system and its installation at the Harley Street Proton Therapy Centre
1511808112_surgeon.jpg
January 09 2018
The device can now be sold to aid in heart treatment throughout the European Union
Frosties Box
December 05 2017
The company is a pioneer in the human microbiome, which is essentially the bacteria that inhabits the gut and skin

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use